Evidence map›Paper›PMID 36446447›Full record

ArticleBMJ global health2022

Lessons for the HIV response from structural innovations catalysed by COVID-19.

Michael Isbell, Linda-Gail Bekker, Beatriz Grinsztejn, Jennifer Kates, Adeeba Kamarulzaman, Sharon R Lewin, Kenneth Ngure, Nittaya Phanuphak, Anton Pozniak, Anna Grimsrud

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMJ global health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Michael IsbellConsultant, New York, New York, USA mtisbell@aol.com.
Linda-Gail BekkerThe Desmond Tutu HIV Centre, University of Cape Town, Rondebosch, South Africa.
Beatriz GrinsztejnEvandro Chagas National Institute of Infectious Diseases, Oswaldo Cruz Foundation (FIOCRUZ), Rio de Janeiro, Brazil.
Jennifer KatesHenry J Kaiser Family Foundation, Washington, District of Columbia, USA.
Adeeba KamarulzamanUniversity of Malaya, Kuala Lumpur, Malaysia.
Sharon R LewinDepartment of Infectious Diseases, The Peter Doherty Institute for Infection and Immunity Melbourne, University of Melbourne, Melbourne, Florida, Australia.
Kenneth NgureSchool of Public Health, Jomo Kenyatta University of Agriculture and Technology, Nairobi, Kenya.
Nittaya PhanuphakInstitute of HIV Research and Innovation, Bangkok, Thailand.
Anton PozniakDepartment of HIV Medicine, Chelsea & Westminster Hospital NHS Foundation Trust, London, UK.
Anna GrimsrudHIV Programmes & Advocacy, International AIDS Society, Cape Town, South Africa.ORCID 0000-0002-1199-8377

Funding

The FIOCRUZ Therapeutic and Prevention HIV/AIDS Clinical Trials Unit (FioTrials)UM1AI069476 · NIAID · FUNDACAO OSWALDO CRUZ · PI BEATRIZ GRINSZTEJN · 2012 to 2026
$26.3M
Bill & Melinda Gates Foundation INV-002610NIAID NIH HHS UM1 AI069476Wellcome Trust
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

COVID-19HIV InfectionsHumansCOVID-19HIVPublic Health

Identifiers

PMID36446447
PMCPMC9709808

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.